Actively Recruiting
A Study of [14C]-LY4064809 in Healthy Participants
Led by Eli Lilly and Company · Updated on 2026-05-12
8
Participants Needed
1
Research Sites
5 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to determine in healthy participants the percentage of LY4064809 that enters bloodstream after oral administration. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 21 days, not including screening. Participants will remain in the clinical research center for 14 days.
CONDITIONS
Official Title
A Study of [14C]-LY4064809 in Healthy Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Must be healthy based on medical history, physical exam, lab tests, and heart monitoring
- Must have normal blood pressure and pulse rate
- Must have at least one bowel movement per day
- Must have a body mass index (BMI) between 18 and 32 kg/m2
- Must be healthy men or healthy women who are not of childbearing potential
- Healthy men with partners who can become pregnant must use contraception or remain abstinent consistent with local rules
You will not qualify if you...
- History or presence of metabolic, heart, liver, gallbladder, bile duct, digestive, blood, or nervous system disorders affecting drug processing
- Abnormal electrocardiogram (ECG)
- Major surgery within 30 days before study start
- History of cancer within 5 years before screening
- Allergies to LY4064809 or related compounds
- History of severe drug reactions requiring steroids or epinephrine
- Psychiatric conditions preventing study compliance
- Use of medications other than acetaminophen within 14 days before first dose and during clinic stay
- Participation in more than 2 radiolabeled drug studies in last 12 months
- Exposure to significant radiation within 12 months
- Participation in radiolabeled investigational drug trials within 6 months
- Evidence of HIV, Hepatitis B, or Hepatitis C infection
- Significant alcohol intake as judged by investigator
- Use of tobacco, smoking-cessation products, e-cigarettes, or nicotine products within 90 days before dosing and discharge
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fortrea Clinical Research Unit Inc. - Madison
Madison, Wisconsin, United States, 53704-2526
Actively Recruiting
Research Team
T
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
P
Physicians interested in becoming principal investigators please contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here